tirzepatide osa trial Tirzepatide and Semaglutide: Impact on OSA in Obesity

Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial

25.22

★★★★☆4.8 (126)

Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight

29.70

★★★★★4.9 (98)

Tirzepatide is a drug being investigated as a potential treatment for sleep apnea. Tirzepatide has been approved for use in weight management under the brand name Zepbound. However, it is not yet

26.45

★★★★★5.0 (157)

SURMOUNT-OSA Trial Results and Potential Role of Tirzepatide in Treating Obesity-Related Obstructive Sleep Apnea — @atulmalhotra13 and @ljaronne presented Friday at #ADASciSessions. Read a recap in ADA Meeting News: https://t.co/Dg0qxKO7Pp

29.88

★★★★★4.7 (84)

Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?

27.06

★★★★★4.9 (203)

Lilly's weight-loss drug reduces sleep apnea severity in late-stage trials

25.78

★★★★★5.0 (176)

In the two SURMOUNT-OSA trials, researchers assessed the efficacy and safety of tirzepatide for the treatment of adults with obstructive sleep apnea and obesity. Full results of both trials and Plain Language

25.94

★★★★★4.8 (132)